Ibrance under the microscope: Real-World data on advanced breast cancer treatment
NCT ID NCT06962969
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed study examined the safety and effectiveness of Ibrance (palbociclib) in women with advanced or metastatic breast cancer using a large real-world database. Researchers looked at side effects and how well the drug worked in everyday practice. The study included adult women with hormone receptor-positive, HER2-negative advanced breast cancer who had received at least one prescription of Ibrance.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Ibrance (palbociclib)
What this could lead to
If successful, this study could confirm that Ibrance is safe and effective in everyday practice for women with advanced breast cancer.
What could go wrong
This is a very small study (only 1 participant) using existing database records, so results may not apply to all patients. It is observational, not a controlled trial.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED OR METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Pfizer New York
New York, New York, 10001, United States